Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Luke R. Jordan is active.

Publication


Featured researches published by Luke R. Jordan.


Nature Communications | 2014

Reconstituting ring-rafts in bud-mimicking topography of model membranes

Yong Sang Ryu; In Ho Lee; Jeng Hun Suh; Seung Chul Park; Soojung Oh; Luke R. Jordan; Nathan J. Wittenberg; Sang Hyun Oh; Noo Li Jeon; Byoungho Lee; Atul N. Parikh; Sin-Doo Lee

During vesicular trafficking and release of enveloped viruses, the budding and fission processes dynamically remodel the donor cell membrane in a protein- or a lipid-mediated manner. In all cases, in addition to the generation or relief of the curvature stress, the buds recruit specific lipids and proteins from the donor membrane through restricted diffusion for the development of a ring-type raft domain of closed topology. Here, by reconstituting the bud topography in a model membrane, we demonstrate the preferential localization of cholesterol- and sphingomyelin-enriched microdomains in the collar band of the bud-neck interfaced with the donor membrane. The geometrical approach to the recapitulation of the dynamic membrane reorganization, resulting from the local radii of curvatures from nanometre-to-micrometre scales, offers important clues for understanding the active roles of the bud topography in the sorting and migration machinery of key signalling proteins involved in membrane budding.


Scientific Reports | 2013

A patterned recombinant human IgM guides neurite outgrowth of CNS neurons

Xiaohua Xu; Nathan J. Wittenberg; Luke R. Jordan; Shailabh Kumar; Jens O. Watzlawik; Arthur E. Warrington; Sang Hyun Oh; Moses Rodriguez

Matrix molecules convey biochemical and physical guiding signals to neurons in the central nervous system (CNS) and shape the trajectory of neuronal fibers that constitute neural networks. We have developed recombinant human IgMs that bind to epitopes on neural cells, with the aim of treating neurological diseases. Here we test the hypothesis that recombinant human IgMs (rHIgM) can guide neurite outgrowth of CNS neurons. Microcontact printing was employed to pattern rHIgM12 and rHIgM22, antibodies that were bioengineered to have variable regions capable of binding to neurons or oligodendrocytes, respectively. rHIgM12 promoted neuronal attachment and guided outgrowth of neurites from hippocampal neurons. Processes from spinal neurons followed grid patterns of rHIgM12 and formed a physical network. Comparison between rHIgM12 and rHIgM22 suggested the biochemistry that facilitates anchoring the neuronal surfaces is a prerequisite for the function of IgM, and spatial properties cooperate in guiding the assembly of neuronal networks.


Disease Models & Mechanisms | 2015

A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis

Xiaohua Xu; Aleksandar Denic; Luke R. Jordan; Nathan J. Wittenberg; Arthur E. Warrington; Bharath Wootla; Louisa Papke; Laurie Zoecklein; Daehan Yoo; Jonah Shaver; Sang Hyun Oh; Larry R. Pease; Moses Rodriguez

ABSTRACT Amyotrophic lateral sclerosis (ALS) is a devastating, fatal neurological disease that primarily affects spinal cord anterior horn cells and their axons for which there is no treatment. Here we report the use of a recombinant natural human IgM that binds to the surface of neurons and supports neurite extension, rHIgM12, as a therapeutic strategy in murine models of human ALS. A single 200 µg intraperitoneal dose of rHIgM12 increases survival in two independent genetic-based mutant SOD1 mouse strains (SOD1G86R and SOD1G93A) by 8 and 10 days, delays the onset of neurological deficits by 16 days, delays the onset of weight loss by 5 days, and preserves spinal cord axons and anterior horn neurons. Immuno-overlay of thin layer chromatography and surface plasmon resonance show that rHIgM12 binds with high affinity to the complex gangliosides GD1a and GT1b. Addition of rHIgM12 to neurons in culture increases α-tubulin tyrosination levels, suggesting an alteration of microtubule dynamics. We previously reported that a single peripheral dose of rHIgM12 preserved neurological function in a murine model of demyelination with axon loss. Because rHIgM12 improves three different models of neurological disease, we propose that the IgM might act late in the cascade of neuronal stress and/or death by a broad mechanism. Summary: A single peripheral dose of a recombinant natural human IgM increases lifespan and delays neurological deficits in mouse models of human ALS.


Expert Review of Neurotherapeutics | 2014

Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases

Nathan J. Wittenberg; Bharath Wootla; Luke R. Jordan; Aleksandar Denic; Arthur E. Warrington; Sang Hyun Oh; Moses Rodriguez

Characterization of binding kinetics and affinity between a potential drug and its receptor are key steps in the development of new drugs. Among the techniques available to determine binding affinities, surface plasmon resonance has emerged as the gold standard because it can measure binding and dissociation rates in real-time in a label-free fashion. Surface plasmon resonance is now finding applications in the characterization of molecules for treatment of neurodegenerative diseases, characterization of molecules associated with pathogenesis of neurodegenerative diseases and detection of neurodegenerative disease biomarkers. In addition it has been used in the characterization of a new class of natural autoantibodies that have therapeutic potential in a number of neurologic diseases. In this review we will introduce surface plasmon resonance and describe some applications of the technique that pertain to neurodegenerative disorders and their treatment.


JAMA Neurology | 2015

Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases

Bharath Wootla; Jens O. Watzlawik; Arthur E. Warrington; Nathan J. Wittenberg; Aleksandar Denic; Xiaohua Xu; Luke R. Jordan; Louisa Papke; Laurie Zoecklein; Mabel L. Pierce; Sang Hyun Oh; Moses Rodriguez

IMPORTANCE Modulating the immune system does not reverse long-term disability in neurologic disorders. Better neuroregenerative and neuroprotective treatment strategies are needed for neuroinflammatory and neurodegenerative diseases. OBJECTIVE To review the role of monoclonal, naturally occurring antibodies (NAbs) as novel therapeutic molecules for treatment of neurologic disorders. EVIDENCE REVIEW Peer-reviewed articles, including case reports, case series, retrospective reviews, prospective randomized clinical trials, and basic science reports, were identified in a PubMed search for articles about NAbs and neurologic disorders that were published from January 1, 1964, through June 30, 2015. We concentrated our review on multiple sclerosis, Parkinson disease, Alzheimer disease, and amyotrophic lateral sclerosis. FINDINGS Many insults, including trauma, ischemia, infection, inflammation, and neurodegeneration, result in irreversible damage to the central nervous system. Central nervous system injury often results in a pervasive inhibitory microenvironment that hinders regeneration. A common targeted drug development strategy is to identify molecules with high potency in animal models. Many approaches often fail in the clinical setting owing to a lack of efficacy in human diseases (eg, less than the response demonstrated in animal models) or a high incidence of toxic effects. An alternative approach is to identify NAbs in humans because these therapeutic molecules have potential physiologic function without toxic effects. NAbs of the IgG, IgA, or IgM isotype contain germline or close to germline sequences and are reactive to self-components, altered self-components, or foreign antigens. Our investigative group developed recombinant, autoreactive, natural human IgM antibodies directed against oligodendrocytes or neurons with therapeutic potential for central nervous system repair. One such molecule, recombinant HIgM22, directed against myelin and oligodendrocytes completed a successful phase 1 clinical trial without toxic effects with the goal of promoting remyelination in multiple sclerosis. CONCLUSIONS AND RELEVANCE Animal studies demonstrate that certain monoclonal NAbs are beneficial as therapeutic agents for neurologic diseases. This class of antibodies represents a unique source from which to develop a new class of disease-modifying therapies.


Journal of the American Chemical Society | 2015

Lipid Membrane Deformation Accompanied by Disk-to-Ring Shape Transition of Cholesterol-Rich Domains.

Yong Sang Ryu; Daehan Yoo; Nathan J. Wittenberg; Luke R. Jordan; Sin-Doo Lee; Atul N. Parikh; Sang Hyun Oh

During vesicle budding or endocytosis, biomembranes undergo a series of lipid- and protein-mediated deformations involving cholesterol-enriched lipid rafts. If lipid rafts of high bending rigidities become confined to the incipient curved membrane topology such as a bud-neck interface, they can be expected to reform as ring-shaped rafts. Here, we report on the observation of a disk-to-ring shape morpho-chemical transition of a model membrane in the absence of geometric constraints. The raft shape transition is triggered by lateral compositional heterogeneity and is accompanied by membrane deformation in the vertical direction, which is detected by height-sensitive fluorescence interference contrast microscopy. Our results suggest that a flat membrane can become curved simply by dynamic changes in local chemical composition and shape transformation of cholesterol-rich domains.


Analytical Chemistry | 2018

Surface Plasmon Resonance Sensing on Naturally Derived Membranes: A Remyelination-Promoting Human Antibody Binds Myelin with Extraordinary Affinity

Milan Vala; Luke R. Jordan; Arthur E. Warrington; L. James Maher; Moses Rodriguez; Nathan J. Wittenberg; Sang Hyun Oh

rHIgM22 is a recombinant human monoclonal IgM designed to promote remyelination, and it is currently in Phase I clinical trials in patients with multiple sclerosis (MS). In animal models of demyelination, a single low dose of rHIgM22 stimulates oligodendrocyte maturation, induces remyelination, preserves axons, and slows the decline of locomotor deficits. Natural autoantibodies like rHIgM22 typically bind to multiple antigens with weak affinity. rHIgM22 binds to oligodendrocytes and myelin. Because the antigens for rHIgM22 is prevalent within and exclusive to central nervous system (CNS) myelin, we used CNS myelin particles in combination with surface plasmon resonance to determine the kinetic and affinity constants for the interaction of rHIgM22 to myelin. We found that both the serum and recombinant forms of the antibody bind to myelin with very small dissociation constants in the 100 pM range, which is highly unusual for natural autoantibodies. The extraordinary affinity between rHIgM22 and myelin may explain why such a low effective dose can stimulate CNS repair in animal models of demyelination and underlie the accumulation of rHIgM22 in the CSF in treated MS patients by targeting myelin.


Lab on a Chip | 2012

Real-time full-spectral imaging and affinity measurements from 50 microfluidic channels using nanohole surface plasmon resonance.

Si Hoon Lee; Nathan C. Lindquist; Nathan J. Wittenberg; Luke R. Jordan; Sang Hyun Oh


Advanced Functional Materials | 2013

Topographically Flat Substrates with Embedded Nanoplasmonic Devices for Biosensing

Jincy Jose; Luke R. Jordan; Timothy W. Johnson; Si Hoon Lee; Nathan J. Wittenberg; Sang Hyun Oh


Nanoscale | 2015

Surface passivation of a photonic crystal band-edge laser by atomic layer deposition of SiO2 and its application for biosensing

Hyungrae Cha; Jeongkug Lee; Luke R. Jordan; Si Hoon Lee; Sang Hyun Oh; Hyo Jin Kim; Juhun Park; Seunghun Hong; Heonsu Jeon

Collaboration


Dive into the Luke R. Jordan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sang Hyun Oh

University of Minnesota

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daehan Yoo

University of Minnesota

View shared research outputs
Top Co-Authors

Avatar

Si Hoon Lee

University of Minnesota

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge